POST-TEST

Cases from the Community: Investigators Discuss the Optimal Management of Chronic Lymphocytic Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Results from the Phase III BRUIN CLL-314 study evaluating pirtobrutinib versus ibrutinib for CLL that was Bruton tyrosine kinase (BTK) inhibitor-naïve and either treatment-naïve or pretreated reported which efficacy finding?**
   a. A statistically significant improvement in progression-free survival (PFS) with pirtobrutinib
   b. Noninferiority in overall response rate (ORR) with pirtobrutinib in both the pretreated and intent-to-treat populations
   c. Noninferiority in ORR with pirtobrutinib in the pretreated population only

2. **Which of the following statements best describes outcomes with fixed-duration first-line acalabrutinib and venetoclax, with or without obinutuzumab, in comparison to chemoimmunotherapy for CLL in the Phase III AMPLIFY trial?**
   a. PFS was improved with acalabrutinib/venetoclax/obinutuzumab but not with acalabrutinib/venetoclax
   b. PFS was improved with both acalabrutinib/venetoclax and acalabrutinib/venetoclax/obinutuzumab, but rates of hypertension and atrial arrhythmia were high
   c. PFS was improved with both acalabrutinib/venetoclax and acalabrutinib/venetoclax/obinutuzumab, with manageable tolerability profiles

3. **What was the approximate reduction in the risk of disease progression or death with first-line pirtobrutinib when compared to bendamustine/rituximab in the Phase III BRUIN CLL-313 study?**
   a. 20%
   b. 40%
   c. 60%
   d. 80%

4. **In the ongoing Phase III SOUNDTRACK-C1 study, the CD19 x CD3 bispecific antibody surovatamig is being evaluated in which of the following settings?**
   a. For patients with CLL with Richter's transformation
   b. For patients who have experienced disease progression on a covalent BTK inhibitor and a Bcl-2 inhibitor
   c. As up-front monotherapy for patients with del(17p) or a TP53 mutation
   d. As consolidation therapy after finite-duration first-line therapy for patients with unmutated IGHV

5. **Pirtobrutinib targets which of the following BTK mutations associated with resistance to covalent BTK inhibitors?**
   a. T474I
   b. C481S
   c. L528W